Large enterprise deals are accelerating, prompting management to raise full-year 2026 guidance for the third time this year.

Relationship-driven sourcing and premium theater formats are preserving entry yields and outperformance even as the company ...

That's a big change for trailing 12-month earnings, since a smaller adjusted profit dropped off and a much larger profit was ...

Owning its network infrastructure lets Bandwidth monetize AI-driven call volume without absorbing the computing costs rivals ...

A decade of aggressive buybacks has shrunk the share count by 37%, amplifying per-share earnings even as revenue growth ...

In its 2027 Long-Term Capital Market Assumptions report published in October 2026, J.P. Morgan projects that Bitcoin ( BTC +0 ...

Microsoft ( MSFT -1.55%) posted results for the fiscal first quarter of 2027 (the three months ending Sept. 30, 2026) on ...

Lee expects several catalysts to fuel that rally. As the largest developer-oriented blockchain for smart contracts and decentralized apps, Ethereum will grow as more stablecoins are minted and more ...

Lilly is the maker of tirzepatide, a drug sold under the name Mounjaro for type 2 diabetes and as Zepbound for weight loss.

Let's consider one company in each category. The one that could benefit from Anthropic's IPO is Broadcom ( AVGO -5.48%), and ...

The e-commerce company has beaten its own forecast all year. Is a cheaper stock enough to buy ahead of the next one?

The only real exceptions to the "claims up, stocks down" rule is the late 1980s, when initial jobless claims started moving ...